Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis
- 30 September 2010
- journal article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 29 (9) , 1014-1020
- https://doi.org/10.1016/j.healun.2010.04.022
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (5P01AI061537-02)
This publication has 42 references indexed in Scilit:
- Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, SwedenScandinavian Journal of Infectious Diseases, 2009
- Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral ValganciclovirAntimicrobial Agents and Chemotherapy, 2009
- Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and EfficacyPLOS ONE, 2009
- Ganciclovir for Cytomegalovirus: a Call for Indefinite Prophylaxis in Lung TransplantationThe Journal of Heart and Lung Transplantation, 2008
- Ganciclovir/Valganciclovir Prophylaxis Decreases Cytomegalovirus-Related Events and Bronchiolitis Obliterans Syndrome after Lung TransplantationClinical Infectious Diseases, 2008
- Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipientsAmerican Journal of Health-System Pharmacy, 2006
- Combined CMV Prophylaxis Improves Outcome and Reduces the Risk for Bronchiolitis Obliterans Syndrome (BOS) after Lung TransplantationTransplantation, 2006
- CytomegalovirusAmerican Journal of Transplantation, 2004
- Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipientsTransplant International, 1999
- Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantationCochrane Database of Systematic Reviews, 1998